Summary Mouse monoclonal antibodies PAb 240 and PAb 1801 which specifically immunoprecipitate p53 protein, were used to examine 27 fresh ovarian tumours (16 serous adenocarcinomas, six endometrioid carcinomas, one mucinous adenocarcinoma, one mucinous borderline tumour and three benign adenomas). Eleven out of 16 (69%) serous adenocarcinomas and one endometrioid tumour showed positive staining with one or both antibodies and none of the mucinous or benign tumours stained with either antibody.
DNA from tumour and peripheral blood leukocytes was used to identify allelic deletions on chromosome 17p in tumours. 11/12 positively staining tumours showed less of heterozygosity (LOH) on 17p at the nearest informative locus to the p53 gene.
In this series of ovarian tumours, LOH on 17p correlates closely with the aberrant expression of the p53 protein in a high proportion of advanced stage serous adenocarcinomas. This observation suggests that the p53 tumour suppressor gene is involved in the evolution of epithelial ovarian cancer (EOC) and may have prognostic significance.
Epithelial ovarian cancer (EOC) is the fourth commonest cause of death in women in the UK (CRC Fact Sheet, 1988) and USA and the leading cause of death from gynaecological malignancy. This is mainly because it presents in the majority of cases as advanced disease. It has a characteristic pattern of transoelomic spread and infrequently spreads beyond the peritoneal cavity. Various prognostic factors have been identified as influencing length of surviyal. These include the extent to which debulking surgery can be achieved, the clinical (FIGO) stage, presence of ascites, histological grade and performance status (Lund, 1990; Heintz, 1988) and many of these latter factors relate to how aggressive the tumour has become.
In his review of recessive mechanisms of malignancy (Green, 1988) , Green commences with the statement 'cancer is a genetic disease'. It is certainly true that sequential genetic changes occur as tumours become more malignant and advanced Vogelstein, 1988) . Many transforming oncogenes have been identified associated with a variety of malignancies including ovarian tumours (Kacinski, 1989; Slamon, 1989) ; recently however much interest had focused in solid tumours on the role of tumour suppressor genes (Green, 1988; Ponder, 1988) which manifest themselves when loss of function (either by mutation or deletion in both alleles) leads to transformation and tumorigenesis.
Techniques using restriction fragment length polymorphisms (RFLP) and radiolabelled probes mapping to known regions of the human genome (Hayes, 1989) (Eccles, 1990; Russell, 1990) , breast (MacKay, 1988; Devilee, 1989) , and colon (Vogelstein, 1989) .
The gene coding for the p53 protein is located on chromosome 17p 13.1 (Isobe, 1986) . The gene product is a 53 kilodalton nuclear phosphoprotein ) first identified in 1979 (Lane, 1979) as a host cell protein to which T antigen is bound in SV40-transformed cells. Normal wildtype p53 (p53-wt) acts as a suppressor of transformation in mouse models (Finlay, 1989) but mutated p53 can act as a dominant transforming oncogene . Wild-type p53 transfected into malignant cells can suppress tumour cell growth (Baker, 1990a) .
Point mutations in highly conserved areas of the gene frequently lead to a conformational change which stabilises the protein and allow it to accumulate in transformed cells. The very low levels present in non-transformed cells are not detectable using routine immunohistochemistry so positive staining is highly suggestive of a mutant gene product . Studies in human colon and lung (Takahashi, 1989; tumours and breast cancer cell lines have shown that mutations in highly conserved regions of the p53 gene are frequently associated with loss of heterozygosity at the l7pl3.1 locus. Expression of mutant p53 protein has been noted in a significant proportion of breast, colon and lung tumours .
In this study, 24 ovarian carcinomas and three benign tumours were examined for loss of heterozygosity on chromosome 17p at or near the p53 gene locus. Immunohistochemistry has been used as a screening test for mutant p53 protein implied by the presence of positive staining due to accumulation of the protein. Frozen sections of the same 27 tumours have been examined using monoclonal antibodies PAb 240 and PAb 1801 which recognise separate specific epitopes on the p53 protein. PAb 240 is specific for an epitope which only seems to be exposed in mutant forms of the protein and PAb 1801 (Banks, 1989 
Polymorphic probes
Five polymorphic probes within the 17p 13 chromosomal segment were used to assess loss of heterozygosity in the tumour compared to blood DNA. The probe pBHP53 maps to 17pl3.1 (Hoyheim, 1989 ) the same region as the p53 gene ( Figure 1 ) and lies within about 10 kb of the p53 gene (Dr J.F. Brown, unpublished results). MCT 35.1 (MCT 35 in Figure 1 ) (Nakamura, 1988 ) is about 2.5 cM and C3068 about 12.5 cM telomeric to BHP53. Information about allele loss at or close to the p53 gene locus was sought first at the BHP53 locus then, if this was uniformative, at the next nearest informative locus to p53. Results were available for two further more distal probes, YNZ 22.2 (YNZ 22 in Figure  1 ) YNH 37.3 (YNH 37 in Figure 1 ), but are not given here because in all cases one of the three closest loci was informative. (Figure 3 ). Sections were interpreted without prior knowledge of the results of LOH studies and scored according to the amount of nuclear staining (Table I) . 
Methods

Results
Positive staining, in all cases of serous type carcinoma was specifically located to the cell nucleus and homogeneous in distribution throughout the malignant cells for each tissue section; stromal cells never stained positive. The overall staining intensity between different tumours was compared by incorporating a standard positive tumour into each run and Statistical analysis (Table II) The Chi-squared test showed a highly significant correlation between positive p53 staining and allele loss at 17p13 (P<0.01).
Discussion
This study shows that aberrant expression of p53 protein is common in ovarian cancer and correlates strongly with loss of heterozygosity close to the p53 gene. It is likely that loss of the p53 tumour suppressor gene is a key event in ovarian carcinogenesis.
Clinical follow-up is too short to draw firm conclusions about the prognostic significance of our findings but in this series of unselected tumours (representative of the clinical spectrum encountered) the serous adenocarcinomas had the highest incidence of positive staining and LOH (62.5%). All but one of the serous tumours (G17) were (Baker, 1990b) suggests that point mutation in the p53 gene is the rate limiting step in tumorigenesis, and the loss of the remaining wild type allele occurs soon afterwards as a tumour passes from benign to malignant.
In one of our cases, strongly positive staining with both monoclonal antibodies was seen where both alleles were retained at BHP53; in contrast four cases showed allele loss of 17p with no immunohistochemical staining of p53 protein.
Although it is possible that allele loss has preceded p53 mutation in the latter three cases, it is also possible that mutant p53 protein has not been recognised by the antibodies used. Alternative explanations include a p53 mutant with a short half life or a mutation to a stop codon in the retained allele such that no p53 is produced by the tumour. Direct sequencing of the p53 gene would clarify these points and this is being undertaken.
It is apparent that loss of function of the p53 gene in this group of tumours is seen most often in the advanced, poorer prognosis disease and supports the view that these events herald a phase of rapid uncontrolled growth of a tumour.
Further studies incorporating more early stage tumours of the major histological types along with direct sequencing of the p53 gene will help to increase our knowledge of the overall pattern of events at the DNA level, which give rise to the pattern of clinical disease we seen in ovarian cancer and may have prognostic and even therapeutic implications for the disease.
